Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Safety of Human USH1C Transgene Expression Following Subretinal Injection in Wild-Type Pigs

P. Kiraly, J. Klein, IP. Seitz, FF. Reichel, T. Peters, T. Ardan, J. Juhasova, S. Juhás, Z. Ellederova, Y. Nemesh, R. Nyshchuk, N. Klymiuk, K. Nagel-Wolfrum, AR. Winslow, U. Wolfrum, J. Motlik, MD. Fischer

. 2025 ; 66 (1) : 48. [pub] 20250102

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010346

PURPOSE: This study aimed to evaluate early-phase safety of subretinal application of AAVanc80.CAG.USH1Ca1 (OT_USH_101) in wild-type (WT) pigs, examining the effects of a vehicle control, low dose, and high dose. METHODS: Twelve WT pigs (24 eyes) were divided into three groups: four pigs each received bilateral subretinal injections of either vehicle, low dose (3.3 × 1010 vector genomes [vg] per eye), or high dose (1.0 × 1011 vg per eye). Total retinal thickness (TRT) was evaluated using optical coherence tomography and retinal function was assessed with full-field electroretinography (ff-ERG) at baseline and two months post-surgery. After necropsy, retinal changes were examined through histopathology, and human USH1C_a1/harmonin expression was assessed by quantitative PCR (qPCR) and Western blotting. RESULTS: OT_USH_101 led to high USH1C_a1 expression in WT pig retinas without significant TRT changes two months after subretinal injection. The qPCR revealed expression of the human USH1C_a1 transgene delivered by the adeno-associated virus vector. TRT changes were minimal across groups: vehicle (256 ± 21 to 243 ± 18 μm; P = 0.108), low dose (251 ± 32 to 258 ± 30 μm; P = 0.076), and high dose (242 ± 24 to 259 ± 28 μm; P = 0.590). The ff-ERG showed no significant changes in rod or cone responses. Histopathology indicated no severe retinal adverse effects in the vehicle and low dose groups. CONCLUSIONS: Early-phase clinical imaging, electrophysiology, and histopathological assessments indicated that subretinal administration of OT_USH_101 was well tolerated in the low-dose treatment arm. OT_USH_101 treatment resulted in high expression of human USH1C_a1. Although histopathological changes were not severe, more frequent changes were observed in the high-dose group.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010346
003      
CZ-PrNML
005      
20250429134644.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1167/iovs.66.1.48 $2 doi
035    __
$a (PubMed)39836403
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kiraly, Peter $u Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom $u Nuffield Laboratory of Ophthalmology, University of Oxford, Oxford, United Kingdom
245    10
$a Safety of Human USH1C Transgene Expression Following Subretinal Injection in Wild-Type Pigs / $c P. Kiraly, J. Klein, IP. Seitz, FF. Reichel, T. Peters, T. Ardan, J. Juhasova, S. Juhás, Z. Ellederova, Y. Nemesh, R. Nyshchuk, N. Klymiuk, K. Nagel-Wolfrum, AR. Winslow, U. Wolfrum, J. Motlik, MD. Fischer
520    9_
$a PURPOSE: This study aimed to evaluate early-phase safety of subretinal application of AAVanc80.CAG.USH1Ca1 (OT_USH_101) in wild-type (WT) pigs, examining the effects of a vehicle control, low dose, and high dose. METHODS: Twelve WT pigs (24 eyes) were divided into three groups: four pigs each received bilateral subretinal injections of either vehicle, low dose (3.3 × 1010 vector genomes [vg] per eye), or high dose (1.0 × 1011 vg per eye). Total retinal thickness (TRT) was evaluated using optical coherence tomography and retinal function was assessed with full-field electroretinography (ff-ERG) at baseline and two months post-surgery. After necropsy, retinal changes were examined through histopathology, and human USH1C_a1/harmonin expression was assessed by quantitative PCR (qPCR) and Western blotting. RESULTS: OT_USH_101 led to high USH1C_a1 expression in WT pig retinas without significant TRT changes two months after subretinal injection. The qPCR revealed expression of the human USH1C_a1 transgene delivered by the adeno-associated virus vector. TRT changes were minimal across groups: vehicle (256 ± 21 to 243 ± 18 μm; P = 0.108), low dose (251 ± 32 to 258 ± 30 μm; P = 0.076), and high dose (242 ± 24 to 259 ± 28 μm; P = 0.590). The ff-ERG showed no significant changes in rod or cone responses. Histopathology indicated no severe retinal adverse effects in the vehicle and low dose groups. CONCLUSIONS: Early-phase clinical imaging, electrophysiology, and histopathological assessments indicated that subretinal administration of OT_USH_101 was well tolerated in the low-dose treatment arm. OT_USH_101 treatment resulted in high expression of human USH1C_a1. Although histopathological changes were not severe, more frequent changes were observed in the high-dose group.
650    _2
$a zvířata $7 D000818
650    12
$a elektroretinografie $7 D004596
650    12
$a optická koherentní tomografie $7 D041623
650    _2
$a prasata $7 D013552
650    12
$a retina $x metabolismus $x patologie $7 D012160
650    12
$a transgeny $7 D019076
650    12
$a genetické vektory $7 D005822
650    12
$a injekce nitrooční $7 D056965
650    _2
$a lidé $7 D006801
650    _2
$a genetická terapie $x metody $7 D015316
650    _2
$a Dependovirus $x genetika $7 D000229
650    _2
$a western blotting $7 D015153
650    _2
$a proteiny buněčného cyklu $x genetika $7 D018797
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a regulace genové exprese $7 D005786
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a cytoskeletální proteiny $x genetika $7 D003598
655    _2
$a časopisecké články $7 D016428
700    1_
$a Klein, Joshua $u Institute of Molecular Physiology, Molecular Cell Biology, Johannes Gutenberg University, Mainz, Germany
700    1_
$a Seitz, Immanuel P $u University Eye Hospital Tübingen, Centre for Ophthalmology, University of Tübingen, Tübingen, Germany
700    1_
$a Reichel, Felix F $u University Eye Hospital Tübingen, Centre for Ophthalmology, University of Tübingen, Tübingen, Germany
700    1_
$a Peters, Tobias $u University Eye Hospital Tübingen, Centre for Ophthalmology, University of Tübingen, Tübingen, Germany $u STZeyetrial GmbH, Tübingen, Germany
700    1_
$a Ardan, Taras $u Institute of Animal Physiology and Genetics, Czech Academy of Science, Libechov, Czech Republic
700    1_
$a Juhasova, Jana $u Institute of Animal Physiology and Genetics, Czech Academy of Science, Libechov, Czech Republic
700    1_
$a Juhás, Stefan $u Institute of Animal Physiology and Genetics, Czech Academy of Science, Libechov, Czech Republic
700    1_
$a Ellederova, Zdenka $u Institute of Animal Physiology and Genetics, Czech Academy of Science, Libechov, Czech Republic
700    1_
$a Nemesh, Yaroslav $u Institute of Animal Physiology and Genetics, Czech Academy of Science, Libechov, Czech Republic $u Department of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Nyshchuk, Ruslan $u Institute of Animal Physiology and Genetics, Czech Academy of Science, Libechov, Czech Republic $u Department of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Klymiuk, Nikolai $u Large Animal Models in Cardiovascular Research, Internal Medical Department I, TU Munich, Munich, Germany
700    1_
$a Nagel-Wolfrum, Kerstin $u Institute of Molecular Physiology, Molecular Cell Biology, Johannes Gutenberg University, Mainz, Germany $u Institute of Developmental Biology and Neurobiology (iDN), Johannes Gutenberg University, Mainz, Germany
700    1_
$a Winslow, Ashley R $u Odylia Therapeutics, Atlanta, Georgia, United States
700    1_
$a Wolfrum, Uwe $u Institute of Molecular Physiology, Molecular Cell Biology, Johannes Gutenberg University, Mainz, Germany
700    1_
$a Motlik, Jan $u Institute of Animal Physiology and Genetics, Czech Academy of Science, Libechov, Czech Republic
700    1_
$a Fischer, M Dominik $u Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom $u Nuffield Laboratory of Ophthalmology, University of Oxford, Oxford, United Kingdom $u University Eye Hospital Tübingen, Centre for Ophthalmology, University of Tübingen, Tübingen, Germany
773    0_
$w MED00002404 $t Investigative ophthalmology & visual science $x 1552-5783 $g Roč. 66, č. 1 (2025), s. 48
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39836403 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134639 $b ABA008
999    __
$a ok $b bmc $g 2311604 $s 1247427
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 66 $c 1 $d 48 $e 20250102 $i 1552-5783 $m Investigative ophthalmology & visual science $n Invest Ophthalmol Vis Sci $x MED00002404
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace